SCHEMBL469856

SCHEMBL469856

O=C1Nc2ccc([N+](=O)[O-])cc2/C1=N/NC(=S)Nc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
MAPT P10636 6/20 0.51
GAA P10253 3/20 0.51
HPGD P15428 1/20 0.51
CA1 P00915 4/20 0.50
CA2 P00918 4/20 0.50
CA12 O43570 3/20 0.50
CA9 Q16790 3/20 0.50
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
MPI P34949 2/20 0.48
PKM P14618 1/20 0.48
GALK1 P51570 1/20 0.48
SAE1 Q9UBE0 1/20 0.48
UBA2 Q9UBT2 1/20 0.48
POLB P06746 2/20 0.47
BLM P54132 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CAPN9 O14815 1/20 0.47
CASP3 P42574 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL469858 0.94 CA1 (0.54) ALDH1A1MAPTGAAHPGDCA1
SCHEMBL13061631 0.88 CA1 (0.49) ALDH1A1MAPTGAAHPGDCA1
SCHEMBL469971 0.87 CA12 (0.49) ALDH1A1MAPTGAAHPGDCA1
SCHEMBL469874 0.87 TTR (0.57) ALDH1A1MAPTGAACA1CA2
SCHEMBL31492004 0.86 KMT2A (0.56) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL18955695 0.86 CA2 (0.62) ALDH1A1MAPTGAACA1CA2
SCHEMBL13008061 0.85 CA12 (0.46) ALDH1A1MAPTGAACA1CA2
SCHEMBL457126 0.85 ALDH1A1 (0.51) ALDH1A1MAPTGAAHPGDCA1
SCHEMBL31491956 0.85 KMT2A (0.47) ALDH1A1MAPTGAAHPGDKMT2A
SCHEMBL31492083 0.85 ALDH1A1 (0.54) ALDH1A1MAPTHPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2240175-B1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY US GOV HEALTH & HUMAN SERV (US) 2013-01-02 EP disclosed
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed
US-20080214606-A1 Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells The Government of the United States of America as represented by The Secretary of the Dept. of ..... (US) 2008-09-04 US disclosed
US-20080214606-A1 Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells The Government of the United States of America as represented by The Secretary of the Dept. of ..... (US) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214606-A1 Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells ABCC1, MCL1, DLD ALDH1A1 1072/4885MAPT 4565/4885GAA 1612/4885
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY ABCC1, ABCB1, ABCC2 ALDH1A1 1607/4885MAPT 4584/4885GAA 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.